<DOC>
	<DOCNO>NCT00110916</DOCNO>
	<brief_summary>The purpose study evaluate clinical response subject symptomatic OA knee follow single 50 mg anakinra , 150 mg anakinra placebo intra-articular ( IA ) injection .</brief_summary>
	<brief_title>Treatment Patients With Osteoarthritis ( OA ) Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Diagnosed knee OA determine American College Rheumatology ( ACR ) criterion Pain define level great 30 mm 100 mm Visual Analogue Scale ( VAS ) No evidence active effusion inflammatory flare , confirm investigator Must exhibit radiographic evidence tibiofemoral compartment knee OA within 12 month screen Stable dos nonprescribed supplement ( e.g . glucosamine chondroitin sulphate , shark cartilage , diacerhein , soya extract ) least 2 month prior screen Unchanged use physical therapy , biomechanical device orthotic support within least 2 month screen Subjects nonsteroidal antiinflammatory drug ( NSAID ) therapy must discontinue NSAIDs 3 day prior baseline ( Day 1 ) Before studyspecific procedure perform , appropriate write informed consent participation study must obtain Malignancy within previous 5 year , except basal cell situ cancer Significant hematologic disease Active infection history recurrent chronic infection Known diagnosis HIV , hepatitis B , hepatitis C infection Uncontrolled diabetes cardiovascular disease hypertension Inflammatory arthropathy include secondary OA Isolated OA patellofemoral joint ( bi tricompartmental involvement exclusion ) Endstage ( `` boneonbone '' ) OA ( Kellgren Lawrence score 4 ) OA hip ipsilateral index knee Total white cell count le 2.0 x 109/L and/or platelet count le 100 x 109/L observe within 1 month precede screen Prior IA injection anakinra experimental interleukin1 ( IL1 ) inhibitor therapy Concurrent treatment subcutaneous ( SC ) anakinra Concurrent recent ( less equal 1 month ) use experimental therapy Prior IA corticosteroid injection within 1 month study Prior viscosupplement therapy within 3 month study Contraindication ( ) IA injection Subjects pregnant breastfeeding , plan become pregnant study Subject use adequate contraception Known allergy E coliderived product Unable understand inform consent Concerns regard subject 's compliance protocol procedure Subject available followup assessment Active substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Intra-articular</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>OA</keyword>
	<keyword>anakinra</keyword>
	<keyword>Amgen</keyword>
</DOC>